Clay Siegall’s Passion For Science And Patients: Seattle Genetics

Clay Siegall received an undergraduate degree in Zoology from the University of Maryland and a Ph.D. in Genetics from the George Washington University. He began his career in various positions at organizations like the National Institute of Health, the National Cancer Institute, and the Bristol-Myers Squibb Pharmaceutical Research Institute.

 

 

In 1998, Dr. Siegall co-founded Seattle Genetics. He is the company’s President, CEO, and Chairman of the Board. As a scientist, he founded Seattle Genetics with the goal of having an emphasis on targeted cancer therapies. Seattle Genetics was founded on scientific innovation, research, and drug development, all created by a passion for helping patients.

 

 

  1. Siegall has led the company to its leadership position it now has in the industry, developing ADCs (antibody-drug conjugates). In 2011, they received FDA approval for its first ADC product, ADCETRIS. Seattle Genetics collaborates with Takeda Pharmaceutical Company to make ADCETRIS a global brand, with approval in over 60 countries. Dr. Siegall’s company is also under-way in the development of a pipeline of proprietary ADCs to help treat cancer, including a novel ADC to be used for acute myeloid leukemia treatment.

 

Under his passionate leadership, the company has entered into numerous strategic licenses for their ADC technology. Their collaborations of licenses involve GlaxoSmithKline, AbbVie, Pfizer, and Genentech. Over $325 million have been generated because of these partnerships.

 

 

Their partnerships have led to over 20 ADCs being developed in the clinical stages using Seattle Genetics’ innovative technology. Dr. Seigall has also been a leader in the company’s capital-raising activities, helping Seattle Genetics acquire over $1.2 billion through both private and public financings. The company had a successful initial public offering in 2001.

 

 

  1. Siegall serves on the Board of Directors at organizations like Alder BioPharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceutical. He has received many awards, like the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. Dr. Siegall is an accomplished author with over 70 publications under his belt. He even holds 15 innovative patents.